Tag: NASH
Can Cara Therapeutics buck the trend?
Cara Therapeutics (NASDAQ: CARA) recently posted its first quarter, 2019 results. The company reported a net loss of $22.0 million, or $0.56 per basic...
Emerging Treatment Paradigms in Focal Segmental Glomerulosclerosis (FSGS)
Focal segmental glomerulosclerosis (FSGS) is a disease caused by the degeneration of glomeruli, the filtering system of the kidney’s and is caused by factors...
Companies Pioneering Novel Solutions to Tackle Obesity
Obesity and overweight together are the leading cause of preventable death in the U.S leading to a loss of 47 percent more life years...
We are looking for talented interns to learn and help investors find valuable companies.